News

Product related press releases are removed after 3 weeks

Press releases are intended for the media. Product-related press releases will only be available upon request after three weeks of publication on our website in order to comply with applicable regulation.

Media

Click here for high resolution pictures for press usage.

Pharmacosmos appoints Henrik Parker as Chief Financial Officer (CFO) and member of the Executive Management, effective 13 November 2023.

Pharmacosmos enters partnership with SteinCares in Latin America

Pharmacosmos initiates Phase II clinical trial of potential new treatment for iron overload in patients with transfusion-dependent β-Thalassemia

Pharmacosmos A/S strengthens the Board of Directors

Tobias S. Christensen appointed new CEO of Pharmacosmos

Pharmacosmos receives Japanese GMP approval

Pharmacosmos acquires AbFero Pharmaceuticals Inc

New study demonstrates advantages of PentaHibe® for cryopreservation of T cells

Pharmacosmos Introduces PentaHibe®

Pharmacosmos establishes subsidiary in China

WHO releases new guidelines on iron deficiency

Pharmacosmos establishes new specialty pharmaceutical company Pharmacosmos Therapeutics, Inc. in the US

New Managing Director in Germany

Pharmacosmos Strengthens Leadership Team

Jacob Tolstrup elected new Chairman of the Board of Directors of Pharmacosmos

Heavy metal impurities found in 94 percent of tested injectable irons for piglets

Pharmacosmos Introduces Pharmaceutical Quality DEAE-Dextran

Improved animal welfare and economy: More live-born baby pigs per litter

Pharmacosmos to initiate large-scale clinical study programme

Pharmacosmos launches new website on novel cryoprotectant Pentaisomaltose®

Pharmacosmos Chief Medical Officer appointed Adjunct Professor

Celebrating 50 years

Pharmacosmos introduces DEAE-Dextran

Product related press releases are removed after 3 weeks

Media

Pharmacosmos

Please identify if you are a: